8 Forces Disrupting Clinical Trials
Clinical development is entering its most consequential inflection point since ICH E6.
The clinical development landscape is shifting. Regulatory expectations have evolved, investor scrutiny has intensified, talent availability has tightened, and technology is advancing faster than most companies can absorb. What does success look like in this new environment? Here are eight forces that have defined—and continue to evolve—the clinical development landscape in 2025 and beyond.
Force 1: Regulatory Agencies Expect Operational Excellence
Regulatory agencies like the FDA and EMA now expect sponsors to demonstrate strong operational discipline and compliance infrastructure across the trial lifecycle. Many trial sites now navigate as many as 22 separate sponsor or CRO digital platforms per study and report spending up to 12 hours each week on redundant data entry, exposing workflow inefficiencies that can threaten regulatory compliance and data quality.
- Auditable workflows and real-time data integrity are effectively non-negotiable; even seemingly minor gaps in documentation or data controls can lead to inspection findings, remediation plans, or, in severe cases, clinical holds and trial suspensions.
- Budget and contract negotiations frequently extend for 60 days or more, creating substantial “white space” in which operational progress stalls and overall timelines drift.
- These delays compress downstream activities, including study start-up, site activation, data collection readiness, and protocol execution, all of which regulators scrutinize for timing, quality, and feasibility in marketing applications and inspections.
- When operational delays accumulate early, they jeopardize regulatory milestones and extend submission timelines, eroding effective patent life and commercial opportunity.
Action: For biotech and pharma R&D leaders, the implication is clear: invest early in robust operational systems (for pharmacovigilance, data management, and regulatory compliance) and harmonized workflows across sponsors and CRO partners to streamline and document trial processes. Organizations that systematically eliminate this “white space” through automation and better orchestration are effectively pulling key milestones forward by weeks to months, gaining an execution advantage equivalent to multiple calendar quarters over slower rivals in competitive indications.
Force 2: AI and Automation Are Becoming Standard, Not Optional
AI-driven trial optimization is now industry standard. The global market for AI in clinical trials reached $9.2 billion in 2025, projected to climb rapidly at a 19% CAGR. AI tools enable smarter site selection, data-driven patient recruitment, and real-time safety signal detection, speeding up timelines and improving accuracy. Trial site selection is increasingly optimized using AI algorithms.
Over 300 ongoing trials are leveraging AI algorithms to accelerate recruitment and monitoring; in oncology, more than 40% of AI-discovered drugs use such technology from Phase I onward. AI/ML platforms are generating an average 18% reduction in trial timelines for companies that deploy them from protocol optimization to automated data cleaning. Still, only 20% of sponsors currently use AI operationally. The majority risk being overtaken by competitors who make the leap now.
- Patient recruitment is driven by real-world data and predictive models.
- Safety signal detection is increasingly systematic rather than anecdotal.
- Data cleaning is progressively automated rather than fully manual.
- Tech-enabled CROs are displacing legacy providers that lack automation and analytics capability.
Companies that implement AI from protocol design through execution are reporting meaningful reductions in trial timelines and fewer protocol amendments, yet a minority of sponsors have fully embedded AI operationally. Those companies that do not keep pace with AI and automation risk being overtaken by competitors that move decisively.
Action: Evaluate and invest in AI solutions across the trial lifecycle—from feasibility and site selection to enrollment oversight, safety, and data quality. Early adopters are already seeing faster site start‑up, fewer avoidable delays, and reduced administrative burden on both sponsors and sites.
Force 3: Embedded Expertise Is Replacing Traditional Outsourcing
The FSP (Functional Service Provider) model is seeing explosive growth, reflecting a move away from the binary “permanent hire vs. outsourced CRO” model. The FSP market hit $18.4 billion in 2025 and is on pace for $30 billion by 2032, an 8.6% annual growth rate.
- Hybrid teams blend core staff with embedded contractors and specialized CRO support, enabling rapid adaptation to shifting pipeline priorities.
- Organizations using hybrid and FSP models are managing complexity, volatility, and resourcing gaps more effectively than those relying solely on traditional structures.
- FSP approaches also reduce internal burdens associated with HR and support functions (such as payroll and benefits), shifting these responsibilities to the provider while preserving continuity and functional depth.
Action: Assess whether your current staffing and outsourcing model is truly nimble. Program-specific partnerships and embedded expertise can accelerate decision-making, de-risk execution, and create a scalable operating model that flexes with trial demand and portfolio shifts.
Force 4: Employment of New Accelerators Positively Impacting Trial Speed
Time to market has always been critical, but the tools available to accelerate development have expanded and become more widely used. Sponsors are leveraging rolling submissions, adaptive designs, and early regulatory engagement to gain tactical speed over slower competitors.
- Rolling submissions allow regulators to begin review before the full dataset is locked.
- Adaptive trial designs enable mid‑course adjustments guided by emerging data.
- Site activation is faster when data driven feasibility and site selection are used upfront.
- Regulatory engagement is moving earlier (for example, pre-IND and ongoing scientific advice meetings) rather than being limited to formal submissions.
- Slow moving trials struggle to attract funding, while fast moving, well managed studies are more likely to retain investor support.
Action: Map your end-to-end timelines, interrogate each major barrier, and systematically implement process and technology accelerators while maintaining quality and patient safety. Organizations that move quickly and validate data earlier are the ones now attracting both patients and capital.
Force 5: Talent Retention Is as Important as Talent Acquisition
High turnover in key roles is eroding institutional memory and slowing execution. Industry analyses, including BDO’s multiyear Clinical Research Organization Global Compensation & Turnover Surveys, have reported annual turnover among clinical research associates & clinical managers in the mid 20% to nearly 30% range, underscoring the scale of churn in core clinical operations roles and contributing to delays and increased risk.
In life‐sciences lab & clinical trial operations, replacing a single FTE can cost 50–125% of annual salary, and up to 300% for specialized or highly experienced roles. These costs reflect not only recruiting and onboarding, but also lost productivity, retention challenges, and the “capacity leakage” that occurs when clinical experts must step away from protocol execution, site support, data review, and other core study activities to train and orient new staff.
By contrast, contractors reduce or eliminate many of these hidden costs. They typically require shorter ramp-up periods, avoid long recruitment cycles, and minimize vacancy-related productivity loss—making them a lower-risk, more flexible option for short- to medium-term specialized roles.
- FSP models and strategic staff augmentation with scalable capacity help mitigate turnover risk by providing experienced reinforcements when internal gaps appear.
- The cost and impact of losing key trial expertise mid-study is now recognized as a board-level concern, with recruitment and onboarding delays stretching trial schedules and raising risk.
Action: Map your trial critical roles (for example, clinical project managers, CRAs, data managers) and estimate the full cost of disruption—including lost time, quality risk, and opportunity cost—not just salary. Redesign your talent strategy to emphasize both retention and risk buffering, using hybrid and FSP models where they can stabilize delivery and protect institutional knowledge.
Force 6: Investor Expectations Have Shifted to Operational Metrics
Investors are evaluating operational excellence as rigorously as scientific potential. Operational audits, process deep dives, and metric-based diligence are now routine in clinical stage investing, particularly for later rounds and strategic partnerships.
- Data quality issues along with repeated missed milestones, and weak regulatory relationships have become major red flags for investors.
- Deals and financings can stall or collapse when sponsors are unable to demonstrate credible delivery capability or to address known compliance gaps.
Action: Build and maintain a robust operational metrics portfolio before entering investor conversations. Include indicators such as milestone adherence, data quality outcomes, inspection and audit history, regulatory engagement track record, and key talent stability. Demonstrating discipline in these areas positions sponsors as lower risk, higher confidence investments.
Force 7: Risk Mitigation Is Becoming Proactive, Not Reactive
Risk management in clinical development is shifting from retrospective “after-action” analysis to proactive, continuously updated mitigation. Top performing organizations design risk controls into protocols and operations from the outset rather than relying on late-stage fixes.
- Modern pharmacovigilance systems and real-time data quality checks reduce patient risk and protocol drift during trial conduct, not only at database lock.
- Integrating structured risk assessments at protocol design and start-up is linked to smoother regulatory interactions and higher trial completion rates.
- Enrollment risk is increasingly mitigated upfront with better site selection, more realistic planning, and diversified recruitment strategies.
Top-performing trial organizations now tie risk mitigation directly to their operating cadence—using continuous monitoring, predictive analytics, and real-time quality controls to surface issues before they escalate. This shift away from episodic, retrospective review is becoming a defining marker of high-maturity clinical operations.
Action: Build formal, proactive risk mitigation plans into both protocol design and operational processes. Sponsors that anticipate and manage risk early avoid expensive remediation, protect patients and data integrity, and maintain stronger relationships with regulators.
Force 8: Regulatory Relationships Matter More Than Ever
Regulators are evaluating not only clinical results but also sponsors’ operational maturity and reliability as long-term partners. Early, consistent engagement with agencies is translating into tangible benefits in both speed and predictability of review.
- Sponsors that maintain strong, proactive relationships with regulators often see faster approvals and smoother review cycles.
- Agency interactions are increasingly central to decision-making, shaping trial design, endpoints, and development strategy rather than simply validating completed work.
- The expertise, preparedness, and credibility of your cross functional team influence how regulators interpret your submissions and respond to your proposals.
Regulators increasingly reward sponsors who demonstrate preparedness, transparency, and scientific rigor throughout development—not just at submission. Organizations that treat regulators as strategic partners rather than final arbiters are seeing more predictable reviews and fewer late-stage surprises.
Action: Make regulatory engagement a core element of your development strategy, not an afterthought. Seek structured feedback during protocol development, maintain transparent communication throughout execution, and build a reputation for operational rigor and scientific depth across your interactions.
The Common Thread
Operational excellence, embedded expertise, and strategic partnership have become decisive differentiators. The organizations
that thrive in 2026 and beyond will:
- Invest early and systemically in operational infrastructure (technology, systems, and end-to-end processes).
- Assemble hybrid teams that combine strong institutional knowledge with flexible specialist support
- Treat speed and efficiency as enduring attributes of the clinical engine, not one-time initiatives.
- Engage regulators early and often and treat risk management as proactive rather than reactive
- Align operational metrics with investor expectations, using transparent data to build confidence and secure continued backing.
About the Author
Dawn McCollough, Lead Clinical Advisor & Clinical Trial Expert
Dawn McCollough brings over 30 years of clinical development experience across the pharmaceutical, biotech, and CRO industries. As a Senior Executive, she has led global trials and programs across all phases and many indications, built high-performing clinical operations teams and organizations, and driven quality and process excellence within major life-science organizations.
